Mylan (MYL) Removed from Citi's US Focus List
Tweet
Share
E-mail
Get Alerts MYL Hot Sheet
Price: $15.86 --0%
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 26
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 26
Join SI Premium – FREE
Mylan (NASDAQ: MYL) is being removed from the US Focus List but analyst Liav Abraham remains constructive on the name following the recent approval of Fulphila and slight delay to the approval of generic Advair.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades AMD to buy with $575 price target ahead of Q4 earnings
- Glenmark Pharmaceuticals Ltd. (GNP:IN) PT Raised to INR2,750 at Investec
- Marvell (MRVL) PT Raised to $345 at B.Riley, bullish on new CEO
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Citi, US Focus ListSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
